Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Gastrointestinal 1Breast 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1

Interventions

Rituximab 531Cyclophosphamide 426Vincristine 219Doxorubicin 193fludarabine phosphate 177Prednisone 167Etoposide 167fludarabine 162Methotrexate 162Cytarabine 157Filgrastim 125Dexamethasone 123Lenalidomide 121Granulocyte Colony-Stimulating Factor 116Whole-Body Irradiation 107Mycophenolic Acid 99ibrutinib 97Bendamustine Hydrochloride 91Tacrolimus 88Melphalan 85Calcium Dobesilate 82Peripheral Blood Stem Cell Transplantation 80Bortezomib 80Busulfan 78obinutuzumab 64ofatumumab 59Radiotherapy 57Cyclosporine 57Brentuximab Vedotin 55Antilymphocyte Serum 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × crenigacestat × Lymphoid × Clear all
NCT01695005 2025-12-26

A Study of LY3039478 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
247 enrolled 53 charts
Lymphoid

Lymphoma, Neoplasm Metastasis, Neoplasms

NCT02518113 2019-09-11

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

Eli Lilly and Company

Phase 1/2 Completed
36 enrolled 17 charts
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡